Benefit-risk paradigm for clinical trial design of obesity devices: FDA proposal

Abstract

Diet and exercise, except in controlled circumstances, have not been shown to provide effective and prolonged weight loss for the majority of those who are obese. Several older drugs intended to reduce weight have been withdrawn from the market, and the new drugs show only modest weight loss. Surgical intervention, specifically procedures that alter the normal gastrointestinal anatomy, does provide prolonged periods of sustained weight loss, with rebound weight gain over time. A variety of medical devices to assist in weight reduction have been studied, but only two are legally marketed devices for obesity. The authors propose a new paradigm for devices intended to treat obesity, based on a benefit-risk determination, with the hope to provide sponsors an a priori tool for systematic assessment of the risks associated with the devices intended for treatment of obesity and to suggest appropriate levels of benefit for devices with different risk levels. The paradigm is not intended to determine the class of a device from a regulatory perspective. This approach was conceived at a Food and Drug Administration (FDA) co-sponsored workshop in October, 2011 and formally presented to an FDA advisory panel for discussion in May 2012.

Evaluation of psoriasis patients’ attitudes toward benefit–risk and therapeutic trade-offs in their choice of treatments

“…Indeed, the 2012 US Food and Drug Administration guidelines from the Center for Devices and Radiological Health on benefit–risk analysis clearly state the importance of considering patients’ preferred treatment when approving medical devices to market 33. The Food and Drug Administration is also using patient feedback and preference DCE evidence to help to facilitate the development and use of patient-centric weight-loss devices for obese patients, a move away from its previous “one-size-fits-all” approach 34,35. In Belgium, DCE studies have been used to consider the importance of decision criteria among citizens with reference to reimbursement,36 whereas the US Centers for Medicare and Medicaid Services uses patient experience surveys to link Medicare payments to health care quality via its Hospital Value-Based Purchasing program 37.…”

Randomized sham‐controlled trial evaluating efficacy and safety of endoscopic gastric plication for primary obesity: The ESSENTIAL trial

“…The study design was developed in consultation with the FDA in support of an expanded indication for the g‐Cath EZ suture anchor, with efficacy end points set per FDA's recommendations in draft guidance . Aftercare was limited to six visits in both groups, consistent with low‐intensity lifestyle therapy .…”

The feasibility of nurse practitioner-performed, telementored lung telesonography with remote physician guidance - ‘a remote virtual mentor’

“…In these studies, novice non-medical users were guided from the ground to generate diagnostic quality images of multiple body regions by ultrasound experts. A spin-off result of this approach included supporting examiners of simulated patients in a variety of test settings [5,6]. Taking advantage of the informatics capabilities of handheld smartphones has led to the demonstration that these devices can themselves be used to facilitate RTMUS [7].…”